Features of cGVHD and treatment in the 10 patients studied
| Patient no./sex/age, y . | Diagnosis . | Type of transplant . | Sites of cGVHD . | Beginning of ECP after transplantation (day) . | Prior treatment for cGVHD . | ECP duration (mo) . | Response . |
|---|---|---|---|---|---|---|---|
| 1/M/45 | CML | MUD | Skin, joints, mouth, liver, eyes | 204 | Prednisone, MMF, CSA | 10 | PR |
| 2/F/25 | CML | RA | Skin, mouth, eyes | 101 | Prednisone, MMF, CSA | 11 | PR |
| 3/F/49 | NHL | RA | Skin, joints, mouth, eyes | 600 | Prednisone, tacrolimus, MMF, CSA | 9 | PR |
| 4/M/45 | CLL | RA | Skin, joints, mouth, eyes | 496 | Prednisone, MMF, CSA | 16 | PR |
| 5/M/53 | NHL | RA | Skin, eyes, lungs | 122 | Prednisone, MMF, CSA | 4 | NC |
| 6/F/36 | AML | MUD | Skin, myositis | 230 | Prednisone, CSA, MMF | 4 | PR |
| 7/M/59 | AML | RA | Skin, joints, mouth, eyes | 189 | Prednisone, MMF, CSA | 12 | NC |
| 8/M/55 | AML | MUD | Skin, mouth, eyes, liver | 457 | Prednisone, CSA, MMF, HC | 4 | PR |
| 9/M/58 | CML | MUD | Skin, joints, mouth | 2928 | Prednisone, tacrolimus | 9 | PR |
| 10/M/53 | CML | RA | Skin, eyes, liver, mouth | 1342 | Prednisone, MMF, CSA, HC, thalidomide | 9 | Stable |
| Patient no./sex/age, y . | Diagnosis . | Type of transplant . | Sites of cGVHD . | Beginning of ECP after transplantation (day) . | Prior treatment for cGVHD . | ECP duration (mo) . | Response . |
|---|---|---|---|---|---|---|---|
| 1/M/45 | CML | MUD | Skin, joints, mouth, liver, eyes | 204 | Prednisone, MMF, CSA | 10 | PR |
| 2/F/25 | CML | RA | Skin, mouth, eyes | 101 | Prednisone, MMF, CSA | 11 | PR |
| 3/F/49 | NHL | RA | Skin, joints, mouth, eyes | 600 | Prednisone, tacrolimus, MMF, CSA | 9 | PR |
| 4/M/45 | CLL | RA | Skin, joints, mouth, eyes | 496 | Prednisone, MMF, CSA | 16 | PR |
| 5/M/53 | NHL | RA | Skin, eyes, lungs | 122 | Prednisone, MMF, CSA | 4 | NC |
| 6/F/36 | AML | MUD | Skin, myositis | 230 | Prednisone, CSA, MMF | 4 | PR |
| 7/M/59 | AML | RA | Skin, joints, mouth, eyes | 189 | Prednisone, MMF, CSA | 12 | NC |
| 8/M/55 | AML | MUD | Skin, mouth, eyes, liver | 457 | Prednisone, CSA, MMF, HC | 4 | PR |
| 9/M/58 | CML | MUD | Skin, joints, mouth | 2928 | Prednisone, tacrolimus | 9 | PR |
| 10/M/53 | CML | RA | Skin, eyes, liver, mouth | 1342 | Prednisone, MMF, CSA, HC, thalidomide | 9 | Stable |
CML indicates chronic myelogenous leukemia; MUD, matched unrelated donor; MMF, mycophenolate mofetil; CSA, cyclosporine; PR, partial response; RA, allograft from related donor; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; NC, no change; AML, acute myelogenous leukemia; and HC, hydroxychloroquine.